

¹³C-Spirulina Gastric Emptying Breath Test Kit “GEBT”

1. Intended Use [IVD]

The Gastric Emptying Breath Test (GEBT), to be used with the GEBT test meal, is intended for use in the measurement of the rate of gastric emptying of solids and as an aid in the diagnosis of delayed gastric emptying (gastroparesis) in adult humans who are symptomatic for gastroparesis. For these purposes, the test system utilizes a Gas Isotope Ratio Mass Spectrometer (GIRMS) for the measurement of the ratio of ¹³CO₂ to ¹²CO₂ in breath samples.

The GEBT procedure should be administered under supervision of a health care professional although no specialized facilities or specially licensed personnel are required.

1.1 Intended Purpose [IVD]

The ¹³C-Spirulina Gastric Emptying Breath Test (GEBT) is intended for use in the measurement of the rate of gastric emptying of solids and as an aid in the diagnosis of delayed gastric emptying (gastroparesis) in adult humans who are symptomatic for gastroparesis.

¹³C-Spirulina GEBT is an In-Vitro Diagnostic (IVD) device that includes the GEBT test meal and a breath collection kit. It is non-automated and semi-quantitative. Gastric emptying (GE) rates are reported quantitatively in terms of ¹³CO₂ excretion rates (kPCD min⁻¹), but diagnosis (qualitative) is determined by comparing ¹³CO₂ excretion rates with a reference range cut-off value that determines whether the GE rate is normal or delayed at each time point. Patient breath samples are collected before and after consumption of the ¹³C-labeled GEBT test meal, then shipped to Cairn’s Clinical Laboratory for analysis of the ratio of ¹³CO₂/¹²CO₂, using a CE marked (Class A, general use) automated breath carbon analyzer gas isotope ratio mass spectrometer (ABCA GIRMS).

Calculation of a subject’s GEBT results is performed by the reference laboratory located in the United States and is reported to the health care provider.

2. Summary and Explanation

2.1 Description of Gastroparesis and Patient Populations(s)

Gastroparesis (delayed gastric emptying) is a common cause of nausea, vomiting, early satiety, postprandial fullness and other upper gut symptoms in individuals referred to gastroenterologists.^{1,2} Gastroparesis is a form of gastric paralysis causing significant morbidity.³ Weight loss, malnutrition and dehydration may be prominent in severe cases and may require tertiary care.^{2, 3, 4} While the true prevalence of gastroparesis is unknown, it is estimated to occur in 20% - 40% of individuals with diabetes mellitus, particularly type I diabetes mellitus, and may be present in 25% - 40% of individuals with functional (non-ulcer) dyspepsia, a condition affecting approximately 20% of the US general population.¹ In diabetics, gastroparesis may adversely affect glycemic control. The etiology of gastroparesis is diverse; the main categories are diabetic, idiopathic and post-surgical.^{1, 2, 3, 4} Virtually any disease or condition that can induce neuromuscular dysfunction of the gastrointestinal tract may cause gastroparesis.³

Generally, there is only weak correlation between symptom severity and the degree of gastric stasis in gastroparetics. In diabetics, the correlation between global gastric symptoms and rates of gastric emptying is poor. Gastroparesis is typically diagnosed based on the presence of appropriate symptoms/signs, confirmation of delayed gastric emptying, and the absence of an obstructing structural lesion in the stomach or small intestine.^{1, 2, 3, 4}

Symptoms of gastroparesis are not significantly dissimilar to symptoms characteristic of various GI conditions (e.g., functional dyspepsia, gastroesophageal reflux disease GERD, dumping syndrome, peptic ulcer disease, etc.). Hence, assessment of gastric motility can be important for the purpose of differential diagnosis and proper treatment planning in patients symptomatic for or suspected of having gastroparesis.

Management of delayed gastric emptying is focused on dietary changes, nutritional support, pharmacologic intervention with antiemetic and prokinetic agents in most individuals, and correction of glycemic control in diabetics. Individuals who are unresponsive to initial treatment can be difficult to manage and may require switching and/or combining of prokinetic and antiemetic agents. Endoscopic venting and feeding tubes utilized in accordance with symptoms and nutritional requirements result in reduced need for hospitalization with refractory gastroparesis. Evolving treatments have been used in some difficult cases, including injecting botulinum toxin in the pylorus and implanting a gastric electric stimulator.^{1, 2, 3, 4}

2.2 GEBT as a Surrogate Test for Gastric Scintigraphy

The GEBT is a non-radioactive, non-invasive, orally administered test for measurement of the rate of solid phase gastric emptying in adults. The GEBT has been validated against the gold standard reference method of gastric scintigraphy.⁵ Performance characteristics of the GEBT compared to gastric scintigraphy are reported in Section 11. The GEBT may be administered in a primary care facility, clinic or tertiary care setting.

The test procedure should be administered under supervision of a health care professional, although no specialized facilities or specially licensed personnel are required.

3. Description/Principle of the GEBT

3.1 Description of ¹³C-Spirulina Diagnostic Substrate

The GEBT is a non-radioactive breath test utilizing the stable isotope carbon-13, denoted as ¹³C. ¹³C stable isotope labeling is inherently safe as 1.1% of all the carbon in nature, our bodies and in the food we eat is ¹³C, with the remaining 98.9% being ¹²C.

Spirulina is a safe, edible, highly digestible blue-green microalga. In the US, Spirulina is primarily consumed as a health food due to its rich nutritional qualities. The recommended amount of Spirulina as a dietary supplement ranges from 3 to 4.5 grams per day. The dose of ¹³C-Spirulina in each GEBT meal is approximately 0.1 grams. Spirulina was acknowledged as a “legally marketed” food by the US FDA in 1981.⁶ In 2011 the Dietary Supplements Information Expert Committee (DSI-EC) of the United States Pharmacopeia (USP) performed a comprehensive review of information related to safety and toxicology of Spirulina and subsequently unanimously voted to grant Class A safety assignment (i.e., “available evidence does not indicate a serious risk to

health or other public health concern that precludes admission of quality monographs into US-NF when these dietary ingredients are properly identified, formulated, and used”) to Spirulina platensis and Spirulina maxima.⁷ Based on this decision, USP has verified Spirulina as a dietary ingredient and is currently developing a quality monograph for Spirulina.⁷

The ¹³C-Spirulina used in the GEBT meal is cultured in a >95% ¹³C enriched medium, resulting in full ¹³C-labeling of nearly all of the algae’s carbon containing nutrients. During GEBT administration, ¹³C-Spirulina particles are bound to the re-hydrated, cooked egg meal and travel with the solid phase of the test meal. The ¹³C-label is released after the GEBT meal exits the stomach during digestion. In the upper small intestine, the absorption of ¹³C-Spirulina follows the same pathways as the absorption of other macronutrients.

3.2 Principle of the GEBT

After providing duplicate pre-meal breath samples, the individual being tested consumes the standard GEBT meal consisting of 27 grams of re-hydrated, pasteurized scrambled egg mix containing a dose of 43 mg of ¹³C (provided by approximately 100 mg of ¹³C-Spirulina), 6 saltine crackers, and 6 fl oz (180 mL) of potable water. The caloric value of the meal is approximately 230 kCal. As the egg meal containing the ¹³C-Spirulina is triturated by the stomach to a particle size of 1 – 2 mm, it passes through the pylorus into the intestine. In the intestine, the labeled products of ¹³C-Spirulina digestion (proteins, carbohydrates, and fats) are absorbed and metabolized giving rise to ¹³C-labeled carbon dioxide expired in the breath. Breath samples, collected periodically in capped glass tubes before and after test meal administration, are returned to a central laboratory for analysis by Gas Isotope Ratio Mass Spectrometry (GIRMS) to determine the ratio of ¹³CO₂/¹²CO₂ in each sample. By measuring the change in this ratio over time as compared to the pre-meal value, the rate of ¹³CO₂ excretion can be calculated and the individual’s gastric emptying rate determined.

3.3 GEBT Configuration

The GEBT procedure is conducted over a 4 hour period. Following an overnight (or 28 hour) fast, duplicate pre-meal breath samples are collected from the test subject. Two pre-meal samples are collected to ensure that in the event of breakage, leakage or a lost sample, there is a “back-up” available in order to establish a subject’s baseline ¹³CO₂ level. The first intact sample of the two pre-meal samples will be analyzed to establish the subject’s baseline ¹³CO₂ value. Following pre-meal sample collection, the subject is administered the test meal. Single post-meal breath samples are subsequently collected at 45, 90, 120, 150, 180, and 240 minutes from the end of test meal consumption.

3.4 Attributes of the GEBT Meal

The emptying time of the GEBT meal was determined by scintigraphy and is similar to low-fat egg meals utilized with scintigraphy. Table 1 displays the average fraction (%) of GEBT meal retained in the stomach of healthy subjects over the 4-hour GEBT evaluation period.

Table 1. Scintigraphic Fraction of GEBT Meal Retained (N=30 healthy subjects)

| Measurement Time | 0 Min | 45 Min | 90 Min | 120 Min | 150 Min | 180 Min | 240 Min |
|----------------------|-------|--------|--------|---------|---------|---------|---------|
| % Test Meal Retained | 100 | 66 | 34 | 18 | 9 | 4 | 1 |

By contrast, Table 2 displays the average fraction (%) of test meal retained in delayed subjects over the 4-hour GEBT evaluation period.

Table 2. Scintigraphic Fraction of GEBT Meal Retained (N=57 delayed subjects*)


| Measurement Time | 0 Min | 45 Min | 90 Min | 120 Min | 150 Min | 180 Min | 240 Min |
|----------------------|-------|--------|--------|---------|---------|---------|---------|
| % Test Meal Retained | 100 | 80 | 65 | 53 | 42 | 31 | 16 |

*Scintigraphically delayed subjects who participated in ABD validation study PRO-CD-004

Figure 1 graphically contrasts the average scintigraphic emptying profiles of healthy vs. delayed (gastroparetic) subjects administered the GEBT meal.

Utilizing a GEBT meal containing 200 mg of ¹³C-Spirulina (twice the carbon-13 dose in the standardized GEBT meal), the carbon-13 washout period was assessed and determined to be 24 hours. Hence, the GEBT may be administered as often as every 24 hours.

Figure 1. Average Fraction of Test Meal Retained in the Stomach vs. Time (as Measured by Scintigraphy)



The normal, inherent, day-to-day, within-subject biologic variability of gastric emptying is substantial. Biologic variability was assessed by GEBT and scintigraphy in patients with normal gastric emptying and patients with slightly (marginally) delayed gastric emptying. Table 3 displays the standard deviation (SD) and % coefficient of variation (%CV) of within-subject biologic variability (BV) at each measurement time for each respective test method using the GEBT meal. Each test subject was given the standardized GEBT twice; test administration was conducted on independent days.

Within-subject biologic variability is similar when measured by either test method (GEBT vs. scintigraphy).

Table 3. Within-Subject Biologic Variability (BV) of Gastric Emptying

| Procedure | Class | N | Measurement Time in minutes, measured from the end of test meal ingestion | | | | | |
|-----------------------------------|--------------------|----|---|-------|------|------|------|------|
| | | | 45 | 90 | 120 | 150 | 180 | 240 |
| GEBT (SD) _{lev} | Normal | 25 | 4.9 | 7.4 | 6.7 | 5.0 | 4.8 | 3.60 |
| GEBT (%CV) _{lev} | | | 19.9 | 15.3 | 11.5 | 8.2 | 8.0 | 7.2 |
| Scintigraphy (SD) _{lev} | | | 7.2 | 8.0 | 7.1 | 6.3 | 4.9 | 1.8* |
| Scintigraphy (%CV) _{lev} | Marginally Delayed | 20 | 20.50 | 12.20 | 8.50 | 5.50 | 3.60 | 1.7* |
| GEBT (SD) _{lev} | | | 2.9 | 5.0 | 5.3 | 5.8 | 5.0 | 2.2 |
| GEBT (%CV) _{lev} | | | 12.8 | 11.9 | 10.3 | 10.4 | 8.7 | 3.9 |
| Scintigraphy (SD) _{lev} | 8 | 8 | 8.2 | 6.5 | 7.4 | 8.9 | 7.5 | 5.5 |
| Scintigraphy (%CV) _{lev} | | | 24.7 | 11.3 | 10.2 | 11.0 | 8.4 | 5.6 |

*The SD and %CV is low as the stomach is nearly emptied in healthy subjects at this time point

3.5 List of all materials provided with the GEBT kit:

- 3.5.1 1 Pouch of Diagnostic Dosage (¹³C-Spirulina/Egg Mix in a foil pouch with oxygen absorber)
- 3.5.2 6 Saltine crackers (repackaged in a foil pouch with oxygen absorber)
- 3.5.3 1 large (~13 fl oz/390 mL) microwaveable cooking cup
- 3.5.4 1 filling cup (small (~3.5 fl oz/~100 mL) plastic cup with pour spout for transferring water)
- 3.5.5 1 plastic cutlery kit (knife, fork and spoon)
- 3.5.6 2 wrapped, plastic straws
- 3.5.7 8 barcode labeled, glass, breath collection tubes with screw caps
- 3.5.8 1 breath tube holder
- 3.5.9 1 mailer
- 3.5.10 1 GEBT requisition form
- 3.5.11 1 package insert

3.6 List of items needed to perform the GEBT, but not provided with the GEBT Kit:

- 3.6.1 Interval timer or clock.
- 3.6.2 Disposable drinking cup capable of holding 6 fl oz (180 mL) of water.
- 3.6.3 1 cu. Ft. (0.02 m3), 1100-watt microwave oven with turntable.
- 3.6.4 Disposable plate.

4. Contraindications

- 4.1 Individuals with known hypersensitivity to Spirulina, egg, milk or wheat allergens should avoid the GEBT.
- 4.2 Because the GEBT is an indirect multi-compartmental method of measuring gastric emptying, GEBT results may be inaccurate in individuals compromised with significant small bowel, pancreatic, liver and/or lung disease. Consequently, GEBT should not be administered to patients with pulmonary dysfunction (e.g., COPD) and/or small bowel malabsorption.

5. Warnings and Precautions

- 5.1 In vitro diagnostic use only. The GEBT meal containing the diagnostic substrate ¹³C-Spirulina is consumed orally as part of the GEBT diagnostic procedure.
- 5.2 Individuals with severe lactose intolerance may wish to avoid the GEBT, as the test meal contains a small amount of lactose, approximately 2.7 grams.
- 5.3 The performance characteristics for individuals under the age of eighteen (18) years have not been established for this test.
- 5.4 The performance characteristics for pregnant women have not been established for this test.
- 5.5 False positive and false negative results can occur with this test.
- 5.6 Follow the directions for collecting breath samples carefully. Errors in the timing and/or procedure for collecting breath samples may affect test results and necessitate re-testing.
- 5.7 This test should not be performed in individuals who have taken medications known to influence the rate of gastric emptying (e.g., erythromycin, metoclopramide, opiates and anticholinergics) within three (3) days prior to testing. INDIVIDUALS SHOULD STOP SUCH MEDICATIONS ONLY AFTER CONSULTING WITH AND OBTAINING APPROVAL FROM THEIR ATTENDING PHYSICIAN OR THE PHYSICIAN ORDERING THE TEST.
- 5.8 Fasting serum glucose levels of diabetic subjects should be checked before administration of GEBT and the test should only be administered to subjects with a fasting serum glucose level of <275 mg/dL⁹.
- 5.9 After 24 hours there is no residual ¹³CO₂ signal in the breath arising from the ¹³C label contained in the GEBT meal; thus, the GEBT may be administered as frequently as every 24 hours.
- 5.10 The GEBT should not be administered within 24 hours (or the relevant washout period) of other ¹³C breath tests (e.g. the ¹³C-Urea breath test for *H. pylori*).

6. Adverse Events

In total, 321 adult subjects were administered the GEBT during development and validation studies. There were no deaths associated with GEBT studies. There were no serious adverse events associated with the GEBT device or the dual-label test procedure conducted in GEBT studies. There were 20 non-serious adverse events. Of these events, 15 were determined to be unrelated to the GEBT, four were determined to be of uncertain relation to the GEBT, and one was determined to be associated with the GEBT. All four events for which the relationship to the GEBT was considered uncertain were reported by subjects previously determined to be gastroparetic. Additionally, the one event that was determined to be related to the GEBT was reported by a gastroparetic subject. The five reporting subjects complained of nausea and abdominal discomfort after ingesting the test meals, which are symptoms consistent with gastroparesis, especially following food consumption.

Any serious incident that has occurred in relation to the device shall be reported to the manufacturer and the competent authority of the Member State in which the user and/or the patient is established.

GEBT has been authorized for use as an investigational device in investigations of promising pro-kinetic drugs conducted by sponsors other than Cairn under IND approval. In these studies, over 9,000 adult patients have been administered the GEBT. No serious adverse events related to or suspected of being related to the GEBT have been reported in these studies.

7. Shelf Life and Storage

The ¹³C-GEBT Administration Kit should be stored at controlled room temperature*. The kit has an expiry date; do not use a GEBT Kit beyond the expiration date displayed on the kit box.

Collected breath samples should be stored at controlled room temperature*. Ship breath samples to Cairn Diagnostics, in the sample mailer, within three weeks of collection.

*Controlled room temperature: a temperature maintained thermostatically that encompasses the usual and customary working environment of 20°C to 25°C (68°F to 77°F).

8. Subject Preparation

The GEBT should be administered after an overnight fast. No solid food should be consumed, or vigorous activity undertaken within 8 hours prior to the test. Alcohol should not be ingested within 8 hours prior to testing. The individual being tested may consume a small amount of water up to 1 hour before the test, but not more than 4 fl oz (120 mL). Coffee may enhance gastric motility and should not be consumed within 8 hours prior to testing. Subjects should not smoke/use tobacco products (e.g. chewing tobacco, nicotine gum) before or during administration of GEBT. The test administrator should confirm that the individual being tested does not have a known hypersensitivity to Spirulina, egg, milk, or wheat allergens; is not severely lactose intolerant; and has not taken medications known to influence the rate of gastric emptying (e.g., erythromycin, metoclopramide, opiates and anticholinergics) within 3 days of testing.

For diabetic test subjects, a fasting serum glucose level should be obtained to confirm that the patient is in glycemic control as hyperglycemia may produce a clinically significant delay in gastric emptying⁸. Serum glucose should be <275 mg/dL prior to conducting a gastric emptying evaluation⁸. If serum glucose cannot be lowered with insulin to below 275 mg/dL, the GEBT procedure should be re-scheduled for another day when the subject is in glycemic control.

The GEBT procedure should be performed in a comfortable environment. The individual being tested should sit quietly, refrain from smoking, and fast (with the exception of the test meal) for the duration of the test. Limited walking is allowed, when necessary, e.g., use of restroom.

9. GEBT Administration Instructions


GEBT ADMINISTRATION INSTRUCTIONS

1. Confirm fasting requirements have been met: no solid food or liquids (including alcoholic beverages) for 8 hours, with the exception of 4 fl oz (120 mL) water allowed up to 1 hour before the test.
2. Confirm that the patient has not received another ¹³C breath test within 24 hours and if the patient is diabetic, that their blood serum glucose <275mg/dL.
3. Patient should sit quietly, refrain from smoking and (with the exception of the test meal) fast for the duration of the test.
4. Enter the required information into GEBT Requisition Form. ALL patient demographic information is REQUIRED for calculation of test results.
5. Collect two PRE-MEAL breath samples according to the collection procedure described below.
6. Prepare GEBT meal:
 - Empty the contents of the GEBT Diagnostic Dosage pouch into the cooking cup and remove the oxygen absorber.
 - Using the graduated filling cup, add 3 fl oz (90 mL) potable water to the GEBT Diagnostic Dosage in the cooking cup to rehydrate.
 - Stir the GEBT Diagnostic Dosage with the spoon provided and cook for 60 seconds in a 1100 Watt microwave (mixture should not be allowed to rehydrate for longer than 5 minutes).
 - Flip the partially cooked GEBT Diagnostic Dosage with the spoon and cook for an additional 30 seconds.
 - CAUTION: cooked GEBT Diagnostic Dosage will be hot.
7. Serve the cooked GEBT Diagnostic Dosage, saltine crackers and 6 oz (180 mL) potable water to the patient. The meal must be consumed within 10 minutes (record time on GEBT requisition form).
8. Set a timer for post meal breath collection as soon as the patient has fully consumed the meal.
9. Collect post-meal breath samples at **45, 90, 120, 150, 180, and 240** minutes from time of completion of the meal according to the collection procedure described below.
10. Return a copy of the completed GEBT requisition form and collected breath samples in the breath sample tube transport container to Cairn Diagnostics in the provided mailer.

BREATH SAMPLE COLLECTION PROCEDURE

1. Remove the cap from breath sample tube and insert straw in tube.
2. Instruct the patient to:
 - Hold tube in comfortable position.
 - Take a deep breath and pause momentarily.
 - Blow gently into the tube for 5-10 seconds.
 - Slowly withdraw straw from tube while still blowing into tube.
3. Immediately cap the tube securely (over tightening may cause the septum cap to collapse). If the cap is cross-threaded upon closing, please remove and recap correctly.
4. Tubes containing breath samples are easily identified by the presence of condensation inside the tube.

NOTE: When the patient is collecting breath samples, make sure they do not inhale the sample back through the straw and only EXHALE into the tube. Inhaling during sample collection may cause non-reportable test results.



10. Quality Control

Breath sample analysis is conducted in a clinical reference laboratory by appropriately trained and licensed personnel. The reference laboratory follows applicable internal quality control procedures. Gas Isotope Ratio Mass Spectrometry (GIRMS) instrumentation used to determine the ¹³CO₂ to ¹²CO₂ ratio in breath is tuned daily to ensure quality control parameters are acceptable. To ensure analytical accuracy, quality control procedures are performed using quality control gases of known ¹³CO₂/¹²CO₂ concentrations.

Properly collected breath samples contain between approximately 3% and 5% CO₂. Breath samples containing less than 1% CO₂ do not contain sufficient CO₂ for accurate determination of the ratio of ¹³CO₂ to ¹²CO₂ and may necessitate re-testing. Test administrators should follow the breath sample collection procedure described in Section 9 above very carefully, to ensure that breath samples can be accurately analyzed.

11. GEBT Results

11.1 The Test Method

Determination of the ratio of ¹³CO₂ to ¹²CO₂ in each breath sample is conducted by the method of Gas Isotope Ratio Mass Spectrometry (GIRMS) at the reference laboratory.

11.2 Calculation of Test Results

Calculation of a subject’s GEBT results is performed by the reference laboratory and reported to the ordering physician. No calculations are required by the ordering physician or test administration personnel.

11.3 Reporting of Test Results

GEBT results are reported using kPCD, a metric which expresses a subject’s ¹³CO₂ excretion rate at each measurement time as defined below.

kPCD: a mathematical expression of a test subject’s ¹³CO₂ excretion rate (per minute, denoted as min⁻¹) at any measurement time t relative to the dose of carbon-13 contained in the test meal.

Simply stated:

kPCD_(t) = 1,000 x [percent dose ¹³C excreted as ¹³CO₂ per minute (min⁻¹) at time t]

GEBT reports include the following information:

1. kPCD results at each measurement time (i.e., kPCD₄₅, kPCD₉₀, etc)
2. Reference range cutoff points for each measurement time
3. Patient status at each time point (Delayed vs. Normal)
4. A graphical display of the patient’s ¹³CO₂ excretion rate (kPCD) vs. time

11.4 GEBT Reference Range Cut-Off Points (COP)

Sixty (60) healthy individuals at two sites provided pre-meal breath samples, were administered the standardized GEBT meal and subsequently provided post-meal breath samples at 45, 90, 120, 150, 180 and 240 minutes from the end of test meal ingestion. All breath samples were analyzed by GIRMS and the breath test metric kPCD was calculated for each sample. The central 95% Reference Interval for the kPCD data set obtained at each respective measurement time was then calculated using RefVal, a computer program implementing the recommendations of the International Federation of Clinical Chemistry on the statistical treatment of reference values.¹⁰ The lower limit of the 95% reference range was established as the cut-off point to diagnose delayed gastric emptying (gastroparesis) by kPCD metric at each time point (Table 4). When using the kPCD metric, the cut-off point (COP) demarcates delayed from normal gastric emptying. For example, at the 90 minute measurement time, a patient having a kPCD result <26.9 min⁻¹ would be classified as positive for delayed emptying (gastroparetic).

Table 4. GEBT Reference Range Cut-Off Points

| Time point | kPCD (min ⁻¹) |
|------------|---------------------------|
| 45 min | 12.9 |
| 90 min | 26.9 |
| 120 min | 34.4 |
| 150 min | 39.5 |
| 180 min | 43.0 |
| 240 min | 35.0 |

11.5 Interpretation of GEBT Results

The GEBT measures the rate of ¹³CO₂ excretion after consumption of a ¹³C-enriched test meal. As the ¹³C enriched meal is emptied from the stomach it is digested, assimilated and ¹³CO₂ is excreted in the breath. At any given measurement time t, the ¹³CO₂ excretion rate is related to the rate of gastric emptying. A larger kPCD value means a faster ¹³CO₂ excretion rate which is proportional to a faster rate of gastric emptying.

In subjects with normal gastric emptying, ¹³CO₂ excretion rates obtained by GEBT generally rise to a maximum between 120 and 180 minutes and then start to decrease because nearly all of the of the ¹³C-labeled test meal has been emptied from the stomach. In subjects with delayed emptying, ¹³CO₂ excretion rates likewise start to rise after ingestion of the meal, but rates are lower and rarely reach a maximum before the end of the evaluation period (240 minutes) as a significant portion of the meal remains in the stomach and digestion and assimilation are incomplete. Because excretion curves

Figure 2. Discrimination between Normal, Delayed and Borderline Subjects by GEBT





Figure 3. Discrimination between Normal, Delayed and Borderline Subjects by Scintigraphy



The contrasting shape of the excretion curves of normal vs. delayed subjects is informative. Although the curves in Figure 2 and 3 appear fairly similar, note that at later time points (180 and 240 minutes) the ¹³CO₂ excretion curve obtained by breath test from subjects with normal rates of gastric emptying declines while the scintigraphic curve does not. With breath test, in normal emptying subjects, the assimilated ¹³C-label will take longer than 4 hours to entirely leave the body and will continuously decline with time, whereas with scintigraphy, physical emptying in normal subjects is observed to be entirely complete (or nearly so) at 4 hours (e.g., the fraction of test meal emptied approaches 100% and cannot come down). However, note that in delayed subjects, emptying curves obtained by both test methods are similar; they are lower and generally continue to rise during the evaluation period.

As further demonstrated in Figures 2 and 3 above, some patients will have consistent test results across all time points (i.e., Normal at all time points, or Delayed at all time points) and are easily classified as having either a Normal or Delayed rate of gastric emptying.

However, as reported in the scintigraphic literature, a considerable number of symptomatic patients have rates of gastric emptying that reside close to the cut-off points (COPs) that demarcate Normal from Delayed emptying (i.e., borderline test results). In such patients, scintigraphic diagnostic classifications may conflict across measurement times. As with scintigraphy, diagnosis of delayed gastric emptying by GEBT may not be consistent across all time points for some patients. GEBT results are intended to provide supplemental information to the clinician when evaluating a patient for gastroparesis. GEBT test results are best used as a component of an overall evaluation plan that includes the patient's symptomatology (including such validated tools as PAGA-SYM/GCSI scores), clinical history, other laboratory test results and findings from procedures such as endoscopy. Diagnosis of gastroparesis should be made in the context of all available evaluable information.

Examples of patient reports that may be obtained by GEBT are as follows:

- Figure 4: Normal gastric emptying
- Figure 5: Delayed gastric emptying
- Figure 6: Borderline – conflicting diagnostic status at different time points
- Figure 7: Delayed at time points prior to 180 minutes but rising through the normal zone at 180 and 240 minute time points.

12. Validation of GEBT versus Scintigraphy

12.1 Validation Overview

The GEBT was validated against the reference method of gastric scintigraphy. The GEBT validation plan utilized an ordered sequence of four studies; the first three studies were pre-validation studies which determined the test meal matrix and configuration of the GEBT, measured biologic variability and established normal Reference Ranges for GEBT and the gold standard method of gastric scintigraphy. The fourth study was the pivotal validation study.

12.2 Validation Study Design

This study determined the diagnostic concordance (overall diagnostic agreement), sensitivity and specificity of GEBT compared to gastric scintigraphy for the diagnosis of delayed gastric emptying (gastroparesis).


Figure 4. Sample GEBT Report – Patient with Normal Emptying

¹³C-Spirulina Gastric Emptying Breath Test (GEBT) Patient Profile

| Patient Name/ID | Test Date | Physician ID | Account #/ID | Report Date |
|-----------------|------------|--------------|--------------|-------------|
| 04-MC-009 | 3-May-2006 | Dr. Szarka | 12345 | 7-May-2006 |

| Status by kPCD | | | | |
|------------------------|------------------------------|-----------------------------------|--------|--|
| Diagnostic Measurement | Results (min ⁻¹) | Normal Range (min ⁻¹) | Status | |
| kPCD ₄₅ | 30.4 | ≥ 12.9 | Normal | |
| kPCD ₉₀ | 54.2 | ≥ 26.9 | Normal | |
| kPCD ₁₂₀ | 61.2 | ≥ 34.4 | Normal | |
| kPCD ₁₅₀ | 62.2 | ≥ 39.5 | Normal | |
| kPCD ₁₈₀ | 58.9 | ≥ 43.0 | Normal | |
| kPCD ₂₄₀ | 50.4 | ≥ 35.0 | Normal | |

Definition and explanation of GEBT Metric "kPCD": kPCD is a mathematical expression of a test subject's ¹³CO₂ excretion rate (per minute, denoted as min⁻¹) at any measurement time t. kPCD is proportional to the rate of gastric emptying at time t; the higher the kPCD value the faster the rate of gastric emptying at that time point.



kPCD Excretion Curves (kPCD vs. time): Subjects with normal rates of gastric emptying typically display kPCD values that rise into the 120- to 180-minute time range and then decline thereafter. In contrast, kPCD values of delayed patients are lower and generally rise continuously throughout the 4-hour evaluation period.

Lab Director Approval _____ Date _____


Figure 5. Sample GEBT Report – Patient with Delayed Emptying

¹³C-Spirulina Gastric Emptying Breath Test (GEBT) Patient Profile

| Patient Name/ID | Test Date | Physician ID | Account #/ID | Report Date |
|-----------------|-------------|--------------|--------------|-------------|
| 04-MC-039 | 24-Jul-2006 | Dr. Smith | 12345 | 3-Dec-2013 |

| Status by kPCD | | | | |
|------------------------|------------------------------|-----------------------------------|---------|--|
| Diagnostic Measurement | Results (min ⁻¹) | Normal Range (min ⁻¹) | Status | |
| kPCD ₄₅ | 5.3 | ≥ 12.9 | Delayed | |
| kPCD ₉₀ | 6.3 | ≥ 26.9 | Delayed | |
| kPCD ₁₂₀ | 7.9 | ≥ 34.4 | Delayed | |
| kPCD ₁₅₀ | 9.6 | ≥ 39.5 | Delayed | |
| kPCD ₁₈₀ | 10.9 | ≥ 43.0 | Delayed | |
| kPCD ₂₄₀ | 12.8 | ≥ 35.0 | Delayed | |

Definition and explanation of GEBT Metric "kPCD": kPCD is a mathematical expression of a test subject's ¹³CO₂ excretion rate (per minute, denoted as min⁻¹) at any measurement time t. kPCD is proportional to the rate of gastric emptying at time t; the higher the kPCD value the faster the rate of gastric emptying at that time point.



kPCD Excretion Curves (kPCD vs. time): Subjects with normal rates of gastric emptying typically display kPCD values that rise into the 120- to 180-minute time range and then decline thereafter. In contrast, kPCD values of delayed patients are lower and generally rise continuously throughout the 4-hour evaluation period.

Lab Director Approval _____ Date _____


Figure 6. Sample GEBT Report – Patient with Borderline GEBT results

¹³C-Spirulina Gastric Emptying Breath Test (GEBT) Patient Profile

| Patient Name/ID | Test Date | Physician ID | Account #/ID | Report Date |
|-----------------|-------------|--------------|--------------|-------------|
| 04-MC-109 | 21-Dec-2006 | Dr. Smith | 12345 | 3-Dec-2013 |

| Status by kPCD | | | | |
|------------------------|------------------------------|-----------------------------------|---------|--|
| Diagnostic Measurement | Results (min ⁻¹) | Normal Range (min ⁻¹) | Status | |
| kPCD ₄₅ | 15.7 | ≥ 12.9 | Normal | |
| kPCD ₉₀ | 30.5 | ≥ 26.9 | Normal | |
| kPCD ₁₂₀ | 35.8 | ≥ 34.4 | Normal | |
| kPCD ₁₅₀ | 36.2 | ≥ 39.5 | Delayed | |
| kPCD ₁₈₀ | 43.1 | ≥ 43.0 | Normal | |
| kPCD ₂₄₀ | 43.6 | ≥ 35.0 | Normal | |

Definition and explanation of GEBT Metric "kPCD": kPCD is a mathematical expression of a test subject's ¹³CO₂ excretion rate (per minute, denoted as min⁻¹) at any measurement time t. kPCD is proportional to the rate of gastric emptying at time t; the higher the kPCD value the faster the rate of gastric emptying at that time point.



kPCD Excretion Curves (kPCD vs. time): Subjects with normal rates of gastric emptying typically display kPCD values that rise into the 120- to 180-minute time range and then decline thereafter. In contrast, kPCD values of delayed patients are lower and generally rise continuously throughout the 4-hour evaluation period.

Lab Director Approval _____ Date _____


Figure 7. Sample GEBT Report – Patient with Predominantly Delayed GEBT results

¹³C-Spirulina Gastric Emptying Breath Test (GEBT) Patient Profile

| Patient Name/ID | Test Date | Physician ID | Account #/ID | Report Date |
|-----------------|-------------|--------------|--------------|-------------|
| 04-MC-136 | 26-Feb-2007 | Dr. Smith | 12345 | 3-Dec-2013 |

| Status by kPCD | | | | |
|------------------------|------------------------------|-----------------------------------|---------|--|
| Diagnostic Measurement | Results (min ⁻¹) | Normal Range (min ⁻¹) | Status | |
| kPCD ₄₅ | 10.7 | ≥ 12.9 | Delayed | |
| kPCD ₉₀ | 17.1 | ≥ 26.9 | Delayed | |
| kPCD ₁₂₀ | 22.7 | ≥ 34.4 | Delayed | |
| kPCD ₁₅₀ | 30.0 | ≥ 39.5 | Delayed | |
| kPCD ₁₈₀ | 45.1 | ≥ 43.0 | Normal | |
| kPCD ₂₄₀ | 54.9 | ≥ 35.0 | Normal | |

Definition and explanation of GEBT Metric "kPCD": kPCD is a mathematical expression of a test subject's ¹³CO₂ excretion rate (per minute, denoted as min⁻¹) at any measurement time t. kPCD is proportional to the rate of gastric emptying at time t; the higher the kPCD value the faster the rate of gastric emptying at that time point.



kPCD Excretion Curves (kPCD vs. time): Subjects with normal rates of gastric emptying typically display kPCD values that rise into the 120- to 180-minute time range and then decline thereafter. In contrast, kPCD values of delayed patients are lower and generally rise continuously throughout the 4-hour evaluation period.

Lab Director Approval _____ Date _____

The study was a prospective, open-label, method comparison validation study. Enrollment was designed to continue until up to 50, but not less than 45, scintigraphically positive (gastroparetic) individuals had been tested and an overall total of 115 evaluable individuals were tested. A total of 132 subjects were enrolled and 129 of those completed the study. Enrollment is summarized as follows:

1. One-hundred and two (102) subjects were recruited from patients suspected of gastroparesis and scheduled for gastric scintigraphy.
2. Twenty-four (24) subjects were enrolled who had been previously suspected of and evaluated for gastroparesis.
3. To supplement the number of scintigraphically positive subjects, five healthy individuals were enrolled for pharmacological induction of delayed gastric emptying by intravenous injection of atropine.
4. One (1) of 11 diabetic subjects enrolled in the study was an asymptomatic patient from the Diabetology Clinic enrolled upon recommendation of the attending physician.

To eliminate the effects of natural, day-to-day variation in gastric emptying on comparative diagnostic results from scintigraphy and GEBT in this validation study, each individual was simultaneously tested by scintigraphy and GEBT using a dual-label test meal. The term dual-label refers to a test meal that contains both the GEBT labeling material (¹³C-Spirulina) and the labeling substance used in scintigraphy (^{99m}Tc Sulphur colloid). After consuming the standardized GEBT meal containing both labels, gastric emptying testing of each individual was conducted simultaneously by scintigraphy and GEBT at 45, 90, 120, 150, 180 and 240 minute post-meal measurement times.

Of the 129 study subjects who completed the study, protocol deviations affected results for 14 subjects, yielding 115 evaluable subjects. Performance statistics are based on the 115 evaluable subjects.

12.3 Validation Study Results

12.3.1 Performance Characteristics: Diagnosis of Delayed Gastric Emptying

The diagnostic status (delayed vs. normal) of each subject was determined at each measurement time by GEBT and by scintigraphy, using the GEBT and scintigraphic cut-off points (COPs) established prior to conducting the validation study. Diagnostic classification by GEBT was then compared to diagnostic classification by scintigraphy.

In the validation study, the prevalence (positivity rate) of delayed gastric emptying as determined by scintigraphy varied from 22% at 45 minutes to a maximum of ~50% at 120 minutes. Based on diagnostic classification of each patient by each method, GEBT performance characteristics (Sensitivity, Specificity, Concordance, Positive Predictive Value (PPV) and Negative Predictive Value (NPV) vs. Scintigraphy are reported in Table 5.

Performance statistics by GEBT metric are tabulated below. For simplicity, the acronym for the metric "Scintigraphic Fraction of Test Meal Emptied" is Scint_FE.

Table 5. Diagnosis by GEBT vs. Scintigraphy

| Classification (N = 115) | Diagnosis by kPCD vs. Scint_FE at 45, 90, 120, 150, 180 and 240 minutes from the end of test meal consumption | | | | | |
|----------------------------|---|------------------|------------------|------------------|------------------|------------------|
| | 45 | 90 | 120 | 150 | 180 | 240 |
| TP [†] | 16 | 30 | 31 | 29 | 20 | 11 |
| TN [‡] | 84 | 63 | 57 | 60 | 57 | 67 |
| FP [§] | 6 | 2 | 1 | 2 | 7 | 2 |
| FN [¶] | 9 | 20 | 26 | 24 | 31 | 35 |
| Performance Statistics (%) | | | | | | |
| Specificity (95% CI) | 93.3 (88.1-98.5) | 96.9 (92.8-100) | 98.3 (94.9-100) | 96.8 (96.8-100) | 89.1 (81.4-96.6) | 97.1 (93.3-100) |
| Sensitivity (95% CI)** | 64.0 (42.2-83.0) | 60.0 (45.2-72.9) | 54.4 (40.7-65.7) | 54.7 (40.2-67.5) | 39.2 (27.1-53.3) | 23.9 (11.6-37.6) |
| Concordance | 87.0 | 80.9 | 76.5 | 77.4 | 67.0 | 67.8 |
| PPV ^{††} (95% CI) | 72.7 (55.5-89.6) | 93.8 (88.4-100) | 96.9 (90.9-100) | 93.5 (85.3-100) | 74.1 (59.5-89.8) | 84.6 (66.3-100) |
| NPV ^{††} (95% CI) | 90.3 (85.1-95.0) | 75.9 (63.7-78.0) | 68.7 (62.4-74.1) | 71.4 (65.0-77.3) | 64.8 (59.7-70.8) | 65.7 (61.9-70.0) |

* TP: true positive; † TN: true negative; ‡ FP: false positive; § FN: false negative; ¶ PPV: positive predictive value; **CI: confidence interval, bootstrap; †† NPV: negative predictive value

Estimated values of Positive Predictive Value (PPV) and Negative Predictive Value (NPV) vs. Scintigraphy over the range of prevalence rates of gastroparesis reported in the literature from 27% to 57% are also reported (Table 6).

Table 6. Performance Statistics (PPV and NPV) of GEBT vs. Scintigraphy Adjusted for Differing Rates of Prevalence (27% and 57%)

| Time Point | Diagnosis by kPCD vs. Scint_FE at 45, 90, 120, 150, 180 and 240 minutes from the end of test meal consumption | | | | | |
|-----------------------------|---|------------------|------------------|------------------|------------------|------------------|
| | 45 | 90 | 120 | 150 | 180 | 240 |
| PPV 27% Prevalence (95% CI) | 78.0 (62.9-92.5) | 87.8 (73.5-100) | 92.1 (78.6-100) | 85.3 (70.7-100) | 57.0 (38.7-78.2) | 75.3 (50.4-100) |
| NPV 27% Prevalence (95% CI) | 87.5 (81.0-93.4) | 86.8 (82.5-90.5) | 85.4 (81.6-88.5) | 86.3 (81.2-88.8) | 79.8 (76.2-84.0) | 77.5 (74.6-80.8) |
| PPV 57% Prevalence (95% CI) | 92.7 (86.4-98.4) | 96.3 (91.2-100) | 97.7 (93.1-100) | 95.7 (90.1-100) | 82.6 (71.5-94.2) | 91.6 (80.0-100) |
| NPV 57% Prevalence (95% CI) | 66.2 (53.1-78.7) | 64.6 (56.4-72.3) | 61.9 (55.0-68.0) | 61.7 (54.3-68.6) | 52.5 (46.9-59.1) | 49.1 (44.9-53.9) |

12.4 Validation Study Limitations

12.4.1 Tobacco Use

A conclusive effect of tobacco use/smoking upon rates of gastric emptying could not be assessed from the validation study, thus results from current smokers should be interpreted with caution.

12.4.2 H. pylori

A conclusive effect of *H. pylori* on GEBT results was not established from the validation study, thus results from subjects that tested positive for *H. pylori* should be interpreted with caution.

12.4.3 Diagnostic performance statistics

Tables 5 and 6 (Section 12.3.1) demonstrate the performance statistics of GEBT as compared to scintigraphy from the validation study and results do not reflect the diagnostic performance of GEBT as compared to clinical diagnosis of delayed gastric emptying.

13. Bibliography

1. American Gastroenterological Association Medical Position Statement: Diagnosis and Treatment of Gastroparesis. *Gastroenterology*. 2003; 127: 1589-1591.
2. The American Motility Society Task Force on Gastroparesis. Treatment of Gastroparesis: A Multidisciplinary Clinical Review. *Neurogastroenterol Motil*. 2006; 18: 263-283.
3. Park M and Camilleri M. CME/Clinical Reviews; Gastroparesis: Clinical Update. *Am J Gastroenterol*. 2006; 101: 1129-1139.
4. Camilleri M, Parkman HP, Shafi MA, et al. Clinical Guideline: Management of Gastroparesis. *Am J Gastroenterol*. 2013; 108: 18-37.
5. Szarka L, Camilleri M, Vella A, et al. A Stable Isotope Breath Test with a Standard Meal for Abnormal Gastric Emptying of Solids in the Clinic and in Research. *Clin Gastroenterol H*. 2008; 8: 635-643.
6. Spirulina. FDA Talk Paper. June 23, 1981.
7. Marles RJ, Barrett ML, Barnes J et al. United States pharmacopeia safety evaluation of Spirulina. *Crit Rev Food Sci Nutr*. 2011; 51(7):593-604.
8. Camilleri M, Parkman HP, Mehnaz AS, et al. Clinical Guideline: Management of Gastroparesis. *Am J Gastroenterol*. 2013; 108:18-37.
9. Abell TL, Camilleri M, Donohoe K, et al. Consensus Recommendations of Gastric Emptying Scintigraphy: A Joint Report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. *Am J Gastroenterol*. 2008; 103:753-763.
10. Solberg, HE. RefVal: A Program Implementing the Recommendations of the International Federation of Clinical Chemistry on the Statistical Treatment of Reference Values. *Computer Methods and Programs in Biomedicine*, 1995; 48: 247-256.
14. **Name and Place of Business**
Advanced Breath Diagnostics, LLC DBA Cairn Diagnostics
105 Westpark Drive, Suite 150
Brentwood, TN 37027, USA
Phone: +1 615-376-5464
Fax: +1 615-376-6384
Primary Contact: Kerry Bush, President



15. **Date of Issuance**
July 2023



L075R03